Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Robert J. Motzer*, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher M. Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burcin Simsek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
156Scopus
citations
Fingerprint
Dive into the research topics of 'Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.